Stock listing
ASX:1AD AdAlta Ltd. Share Price
Home listing (ASX) of AdAlta Ltd.
Follow AdAlta Ltd. into a list and get an email when it puts out news.
Share price · ASX:1AD
$0.0020 AUD -0.0010 (-33.3%)
Close on Nov 19, 2026
- Day range
- $0.0020 – $0.0025 AUDNov 19, 2026
- Volume
- 1.04M sharesNov 19, 2026
- Market cap
- $6.42M AUDAt the close on Nov 19, 2026 · price × 3.21B shares outstanding
- 52-week range
- $0.0020 – $0.0080 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $6,593 AUDMedian day 434,250 shares · 14 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:1AD · Home | $0.0020 AUD | -0.0010 (-33.3%) | 1,039,875 | $0.0025 | $0.0025 | $0.0020 | $0.0030 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · ASX:1AD · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0020 | -0.0010 | -33.3% | $0.0025 | $0.0025 | $0.0020 | 1,039,875 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | +0.0005 | +20.0% | $0.0030 | $0.0030 | $0.0030 | 3,829,659 | |
| $0.0025 | 0.0000 | 0.0% | $0.0025 | $0.0025 | $0.0025 | 0 | |
| $0.0025 | 0.0000 | 0.0% | $0.0025 | $0.0025 | $0.0025 | 0 | |
| $0.0025 | +0.0005 | +25.0% | $0.0030 | $0.0030 | $0.0025 | 332,396 | |
| $0.0020 | -0.0005 | -20.0% | $0.0020 | $0.0020 | $0.0020 | 800,000 | |
| $0.0025 | 0.0000 | 0.0% | $0.0025 | $0.0025 | $0.0025 | 0 | |
| $0.0025 | -0.0005 | -16.7% | $0.0030 | $0.0030 | $0.0025 | 2,768,955 | |
| $0.0030 | +0.0010 | +50.0% | $0.0030 | $0.0030 | $0.0020 | 2,260,222 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 4,500,000 | |
| $0.0020 | 0.0000 | 0.0% | $0.0020 | $0.0020 | $0.0020 | 0 | |
| $0.0020 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0020 | 131,990 | |
| $0.0020 | -0.0010 | -33.3% | $0.0030 | $0.0030 | $0.0020 | 38,151,684 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0025 | 1,675,309 | |
| $0.0030 | -0.0005 | -14.3% | $0.0035 | $0.0040 | $0.0030 | 45,016,546 | |
| $0.0035 | +0.0005 | +16.7% | $0.0040 | $0.0040 | $0.0035 | 324,080 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | -0.0005 | -14.3% | $0.0030 | $0.0030 | $0.0030 | 410,647 | |
| $0.0035 | +0.0005 | +16.7% | $0.0035 | $0.0035 | $0.0035 | 37,595 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | -0.0010 | -25.0% | $0.0040 | $0.0040 | $0.0030 | 887,750 | |
| $0.0040 | +0.0005 | +14.3% | $0.0040 | $0.0040 | $0.0030 | 928,764 | |
| $0.0035 | +0.0005 | +16.7% | $0.0035 | $0.0035 | $0.0035 | 1,018,571 | |
| $0.0030 | -0.0005 | -14.3% | $0.0035 | $0.0035 | $0.0030 | 315,239 | |
| $0.0035 | 0.0000 | 0.0% | $0.0035 | $0.0035 | $0.0035 | 0 | |
| $0.0035 | 0.0000 | 0.0% | $0.0035 | $0.0035 | $0.0035 | 200,000 | |
| $0.0035 | 0.0000 | 0.0% | $0.0030 | $0.0035 | $0.0030 | 34,720 | |
| $0.0035 | 0.0000 | 0.0% | $0.0030 | $0.0035 | $0.0030 | 1,919,234 | |
| $0.0035 | 0.0000 | 0.0% | $0.0030 | $0.0035 | $0.0030 | 282,311 | |
| $0.0035 | 0.0000 | 0.0% | $0.0035 | $0.0035 | $0.0035 | 147,312 | |
| $0.0035 | -0.0005 | -12.5% | $0.0035 | $0.0040 | $0.0035 | 505,000 | |
| $0.0040 | 0.0000 | 0.0% | $0.0030 | $0.0040 | $0.0030 | 564,463 | |
| $0.0040 | +0.0005 | +14.3% | $0.0040 | $0.0040 | $0.0035 | 3,630,682 | |
| $0.0035 | +0.0005 | +16.7% | $0.0035 | $0.0040 | $0.0035 | 3,525,466 | |
| $0.0030 | -0.0005 | -14.3% | $0.0030 | $0.0030 | $0.0030 | 103,333 | |
| $0.0035 | 0.0000 | 0.0% | $0.0035 | $0.0035 | $0.0035 | 596,875 | |
| $0.0035 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0035 | 51,121 | |
| $0.0035 | -0.0005 | -12.5% | $0.0040 | $0.0040 | $0.0035 | 1,200,000 | |
| $0.0040 | +0.0005 | +14.3% | $0.0040 | $0.0040 | $0.0035 | 534,177 | |
| $0.0035 | 0.0000 | 0.0% | $0.0035 | $0.0035 | $0.0035 | 1,000,000 | |
| $0.0035 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0035 | 1,130,001 | |
| $0.0035 | +0.0005 | +16.7% | $0.0040 | $0.0040 | $0.0030 | 16,203,246 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 730,349 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 116,201 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 500,000 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 2,016,962 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0035 | $0.0030 | 1,620,006 | |
| $0.0030 | -0.0010 | -25.0% | $0.0040 | $0.0040 | $0.0030 | 30,908 | |
| $0.0040 | +0.0010 | +33.3% | $0.0040 | $0.0040 | $0.0030 | 5,497,497 | |
| $0.0030 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0030 | 2,043,275 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 166,667 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 1,899,998 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 74,000 | |
| $0.0030 | 0.0000 | 0.0% | $0.0035 | $0.0035 | $0.0030 | 93,765 | |
| $0.0030 | -0.0005 | -14.3% | $0.0030 | $0.0030 | $0.0030 | 1,498,964 | |
| $0.0035 | -0.0005 | -12.5% | $0.0040 | $0.0040 | $0.0035 | 198,514 | |
| $0.0040 | +0.0005 | +14.3% | $0.0035 | $0.0040 | $0.0030 | 434,250 | |
| $0.0035 | +0.0005 | +16.7% | $0.0040 | $0.0040 | $0.0035 | 471,243 | |
| $0.0030 | -0.0005 | -14.3% | $0.0040 | $0.0040 | $0.0030 | 486,802 | |
| $0.0035 | +0.0005 | +16.7% | $0.0035 | $0.0035 | $0.0035 | 20,000 |
Splits
1 split · ASX:1AD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- ASX:1AD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 16, 2026
EW-001 Orphan Drug Designation, pre-IND update
Latest deck · Sep 10, 2026
BIOSeedin Autumn Innovation Partnering Summit 2026
Conference · 35 slides
Latest news
EW-001 Orphan Drug Designation, pre-IND update
Nov 16, 2026
Closed $0.0030 (+20.0%) on Nov 17, 2026
$1.4m additional RDTI refund
Nov 11, 2026
Closed $0.0025 (+25.0%) on Nov 12, 2026
Letter to Shareholders, Notice of AGM & Proxy Form
Oct 29, 2026
Closed $0.0020 (-33.3%) on Oct 30, 2026
Change of AGM Date
Oct 27, 2026
Closed $0.0030 (-14.3%) on Oct 28, 2026
Quarterly Appendix 4C and Activities Report
Oct 25, 2026
Closed $0.0030 (0.0%) on Oct 26, 2026
RDTI receipt, Advanced Overseas Finding
Oct 18, 2026
Closed $0.0030 (-25.0%) on Oct 19, 2026
EW-001 JDC milestone approvals
Oct 4, 2026
Closed $0.0035 (-12.5%) on Oct 5, 2026
China Representative Office opens
Sep 30, 2026
Closed $0.0040 (+14.3%) on Oct 1, 2026
Date of AGM & Closing Date for Director Nominations
Sep 29, 2026
Closed $0.0035 (+16.7%) on Sep 30, 2026
US FDA grants EW-001 pre-IND meeting
Sep 22, 2026
Closed $0.0040 (+14.3%) on Sep 23, 2026
AdAlta Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 39 in the last 12 months · 188 in all · newest Nov 16, 2026 · oldest 2016
- Decks
- 84 decks · latest Sep 10, 2026
Where AdAlta Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:1AD · Home listing · This page | ASX | Australia | AUD |
| Frankfurt:JDA | Frankfurt | Germany | EUR |
Valuation
Price/book 17.4× against a median of 0.8×: the highest of 9 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 19, 2026
- Enterprise value
- $5.14M AUD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 17.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AdAlta Ltd. · ASX:1AD | US$4.25M | US$3.40M | n/a | n/a | n/a | 17.4× | n/a | 0.0× | n/a |
| NFL Biosciences SA · EURONEXT:ALNFL | US$4.71M | US$5.36M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TheraCryf PLC · LSE:TCF | US$4.64M | US$2.63M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Pulmatrix, Inc. · NASDAQ:PULM | US$4.64M | US$3.24M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | 0.33 |
| AIM ImmunoTech Inc. · AMEX:AIM | US$4.57M | −US$937,186 | n/a | −10.3× | n/a | 0.7× | n/a | 0.2× | 0.66 |
| Tissue Repair Ltd · ASX:TRP | US$4.40M | US$1.24M | n/a | 3.4× | n/a | 0.8× | −958.0% | 0.0× | n/a |
| Processa Pharmaceuticals, Inc. · NASDAQ:PCSA | US$4.37M | −US$175.8M | n/a | n/a | n/a | n/a | n/a | n/a | 1.60 |
| Percheron Therapeutics Limited · ASX:PER | US$3.94M | US$1.27M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Lantern Pharma Inc. · NASDAQ:LTRN | US$3.89M | −US$3.69M | n/a | n/a | n/a | 2.8× | n/a | 0.0× | 2.80 |
| Silo Pharma, Inc. · NASDAQ:SILO | US$3.77M | −US$4.28M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.23 |
| Alzamend Neuro, Inc. · NASDAQ:ALZN | US$3.74M | −US$3.85M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.00 |
| Median of the others | US$4.38M | US$153,720 | −3.5× | 0.8× | −958.0% | 0.0× | 1.42 |
Team and board
Officers
| Officer | Role |
|---|---|
| Tim Oldham | CEO & MANAGING DIRECTOR |
| Cameron Jones | COMPANY SECRETARY |
| Janette Dixon DBA | Head of Business Development |
| Kevin Lynch MBBS | Consultant Chief Medical Officer – Oncology |
Board
| Director | Role |
|---|---|
| Paul MacLeman | CHAIRMAN |
| Fadi Diab | NON-EXECUTIVE DIRECTOR |
| Michelle Burke | NON-EXECUTIVE DIRECTOR |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Aug 26, 2025 | 0.0% |
| Q2 2025 | Feb 20, 2025 | 0.0% |
| Q2 2023 | Feb 27, 2023 · After close | 0.0% |
| Q4 2022 | Aug 28, 2022 · After close | 0.0% |
| Q2 2022 | Feb 22, 2022 · After close | +1.6% |
| Q4 2021 | Aug 26, 2021 · After close | −3.7% |
| Q2 2021 | Feb 25, 2021 · Before open | −5.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| BIOSeedin Autumn Innovation Partnering Summit 2026 | Conference | 35 slides | Sep 10, 2026 |
| Investor Presentation (August 2026) | Investor deck | 35 slides | Aug 13, 2026 |
| ISCT ANZ 2026 Regional Meeting | Conference | 14 slides | Jul 20, 2026 |
| Investor Presentation (April 2026) | Investor deck | 16 slides | May 11, 2026 |
| ANZ Biologics Festival 2026 | Conference | 21 slides | Feb 4, 2026 |
| Investor Presentation (January 2026) | Investor deck | 17 slides | Jan 15, 2026 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 25 slides | Nov 26, 2025 |
| Investor Presentation (August 2025) | Investor deck | 27 slides | Aug 19, 2025 |
| Investor Presentation (July 2025) | Investor deck | 27 slides | Jul 30, 2025 |
| Investor Presentation (May 2025) | Investor deck | 28 slides | May 7, 2025 |
Show 50 decks
This page holds 50 of 84 decks. Open Decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of fully paid ordinary shares with attaching options Announced: A$2.5M · A$0.004 a share · Warrants at A$0.01 · 62 Capital Pty Ltd Dealers: 62 Capital Pty Ltd (lead) Use of proceeds: Advance BZDS1901 CAR-T therapy: obtain US FDA pre-IND guidance and establish Australian manufacturing; execute East to West strategy | May 4, 2026 | US$1.79M |
| Private placement of fully paid ordinary shares with attaching ASX:1ADO options Update: A$1.2M · A$0.005 a share · 62 Capital Pty Ltd Dealers: 62 Capital Pty Ltd (lead) Use of proceeds: Advance AdCella's East to West cell therapy strategy, other transactions, i-body intellectual property and general working capital | Jan 30, 2026 | US$838,637 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 677.0K | 1.74M | 3.47M | 2.76M | 3.99M | 3.85M | 3.54M | 2.02M | 1.80M | |
| Cost of revenue | 219.5K | 229.9K | 29.9K | 260.6K | 7.01M | 7.01M | 32.5K | 3.14K | 5.43K | |
| Gross profit | 457.5K | 1.51M | 3.44M | 987.9K | 848.2K | -6.40M | 3.51M | 2.02M | 1.79M | |
| Research and development | 3.34M | 2.20M | 4.16M | 3.65M | 4.13M | 6.23M | 6.23M | |||
| Selling, general and administrative | 1.19M | 2.56M | 2.40M | 4.19M | 4.33M | 2.94M | 1.41M | 245.0K | 833.9K | 207.0K |
| Operating income | -4.80M | -4.38M | -5.26M | -8.34M | -7.76M | -8.55M | -9.05M | -9.53M | -5.88M | -4.80M |
| Depreciation and amortization | 85.2K | 63.0K | 29.9K | 33.1K | 29.1K | 41.8K | 32.5K | 3.14K | 5.43K | |
| EBITDA | -4.29M | -5.20M | -8.31M | -7.73M | -8.53M | -9.01M | -9.50M | -5.88M | -4.79M | |
| Interest expense | 290.9K | 62.3K | 115.0K | 123.8K | 111.4K | 97.6K | 115.5K | 115.5K | 59.8K | 0 |
| Income before tax | -5.09M | -4.50M | -7.12M | -7.73M | -6.06M | -5.63M | -6.01M | -9.42M | -5.88M | -4.61M |
| Income tax | -404.2K | -677.0K | -1.74M | -2.88M | 111.4K | 97.6K | 115.5K | -3.50M | -2.02M | -1.78M |
| Net income | -4.68M | -4.50M | -5.38M | -4.85M | -6.06M | -5.63M | -6.01M | -5.92M | -3.85M | -2.83M |
| Earnings per share, basic | -0.00 | -0.03 | -0.05 | -0.08 | -0.02 | -0.12 | -0.18 | -0.28 | -0.18 | -0.15 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.28M | 1.31M | 3.34M | 4.79M | 8.66M | 5.79M | 3.37M | 5.56M | 2.31M | 6.22M |
| Short-term investments | -206.3K | 0 | 4.01M | |||||||
| Receivables | 273.6K | 836.0K | 1.82M | 2.49M | 40.0K | 2.98M | 3.31M | 3.58M | 2.08M | 1.84M |
| Inventory | -1.95M | -2.49M | 1 | -2.98M | -3.31M | -3.58M | -2.08M | -1.84M | ||
| Current assets | 1.72M | 2.14M | 5.29M | 7.70M | 10.6M | 8.98M | 6.73M | 9.17M | 4.44M | 8.09M |
| Property, plant and equipment | 0 | 282.1K | 36.0K | 63.8K | 71.7K | 98.6K | 138.1K | 0 | 0 | |
| Total assets | 1.72M | 2.14M | 5.57M | 7.73M | 10.6M | 9.05M | 6.91M | 9.31M | 4.44M | 8.09M |
| Accounts payable | 312.1K | 641.8K | 92.9K | 1.12M | 555.5K | 215.7K | 540.8K | 1.51M | 74.6K | 10.4K |
| Current liabilities | 1.35M | 1.34M | 2.22M | 5.81M | 3.63M | 2.66M | 3.21M | 1.82M | 366.3K | 344.5K |
| Long-term debt | 1.32M | 1.09M | 0 | 1.61M | ||||||
| Total debt | 1.77M | 2.70M | 4.01M | 4.00M | 1.69M | 2.19M | 2.19M | |||
| Total liabilities | 1.35M | 2.74M | 3.54M | 5.82M | 5.27M | 2.66M | 3.21M | 1.82M | 366.3K | 344.5K |
| Shareholders' equity | 370.2K | -598.2K | 2.03M | 1.91M | 5.38M | 6.39M | 3.70M | 7.49M | 4.07M | 7.75M |
| Shares outstanding | 2.05B | 130.6M | 98.9M | 63.7M | 278.4M | 47.3M | 33.7M | 20.8M | 21.6M | 19.2M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4.44M | -2.94M | -5.26M | -5.13M | -4.09M | -4.78M | -5.89M | -5.82M | -3.93M | -3.73M |
| Capital spending | 0 | -3 | -62.4K | -2.13K | -25.2K | -2.12K | -2.38K | -170.6K | -3.14K | -6.75K |
| Free cash flow | -4.44M | -2.94M | -5.32M | -5.13M | -4.11M | -4.78M | -5.89M | -5.99M | -3.93M | -3.73M |
| Cash from investing | 109.6K | -62.4K | -2.13K | -25.2K | -2.12K | -2.38K | -170.6K | -3.14K | -8.35K | |
| Cash from financing | 4.42M | 999.1K | 3.67M | 1.27M | 7.02M | 7.19M | 3.70M | 9.24M | 13.2K | 9.47M |
| Dividends paid | -2.76M | -5.18M | -3.55M | |||||||
| Share buybacks | -81.9K | -185.7K | -286.1K | -70.9K | -266.0K | -327.5K | -153.2K | -716.1K | 13.2K | -584.8K |
| Change in cash | -21.3K | -1.83M | -1.66M | -3.87M | 2.87M | 2.42M | -2.19M | 3.25M | -3.92M | 5.74M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EW-001 Orphan Drug Designation, pre-IND update | Nov 16, 2026 | Operations update | ASX |
| $1.4m additional RDTI refund | Nov 11, 2026 | Results | ASX |
| Letter to Shareholders, Notice of AGM & Proxy Form | Oct 29, 2026 | Meeting notice | ASX |
| Change of AGM Date | Oct 27, 2026 | Meeting notice | ASX |
| Quarterly Appendix 4C and Activities Report | Oct 25, 2026 | Quarterly report | ASX |
| RDTI receipt, Advanced Overseas Finding | Oct 18, 2026 | Results | ASX |
| RDTI receipt, Advanced Overseas Finding | Oct 18, 2026 | Results | ASX |
| EW-001 JDC milestone approvals | Oct 4, 2026 | Other filings | ASX |
| China Representative Office opens | Sep 30, 2026 | Operations update | ASX |
| Date of AGM & Closing Date for Director Nominations | Sep 29, 2026 | Meeting notice | ASX |
All 178 filings
Cap table
Built by 6ix from AdAlta Ltd.’s releases · as of May 4, 2026
- Common shares
- 3,212,169,031
- Fully diluted
- 3,212,169,031
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,212,169,031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,212,169,031 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cameron Jones | COMPANY SECRETARY · Since at least Nov 5, 2026 |
| Fadi Diab | NON-EXECUTIVE DIRECTOR · Since at least Nov 5, 2026 |
| Janette Dixon DBA | Head of Business Development · Since at least Nov 4, 2026 |
| Kevin Lynch MBBS | Consultant Chief Medical Officer – Oncology · Since at least Nov 4, 2026 |
| Michelle Burke | NON-EXECUTIVE DIRECTOR · Since at least Nov 5, 2026 |
| Paul MacLeman | CHAIRMAN · Since at least Nov 5, 2026 |
| Tim Oldham | CEO & MANAGING DIRECTOR · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about AdAlta Ltd.